TCBWF (TC BioPharm (Holdings)) Current Accrued Expense: $2.77 Mil (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is TC BioPharm (Holdings) Current Accrued Expense?

TC BioPharm (Holdings) TCBWF Current Accrued Expense is $2.77 Mil as of Dec. 2024. The stock has 2 warning signs investors should review.

TC BioPharm (Holdings)'s Current Accrued Expense for the quarter that ended in Dec. 2024 was $2.77 Mil.

TC BioPharm (Holdings)'s quarterly Current Accrued Expense declined from Dec. 2023 ($3.05 Mil) to Jun. 2024 ($2.66 Mil) but then increased from Jun. 2024 ($2.66 Mil) to Dec. 2024 ($2.77 Mil).

TC BioPharm (Holdings)'s annual Current Accrued Expense increased from Dec. 2022 ($1.15 Mil) to Dec. 2023 ($3.05 Mil) but then declined from Dec. 2023 ($3.05 Mil) to Dec. 2024 ($2.77 Mil).

TC BioPharm (Holdings) Current Accrued Expense Related Terms

TC BioPharm (Holdings) Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for TC BioPharm (Holdings)'s Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TC BioPharm (Holdings) Current Accrued Expense Chart

TC BioPharm (Holdings) Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Current Accrued Expense
Get a 7-Day Free Trial 1.24 3.10 1.15 3.05 2.77

TC BioPharm (Holdings) Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.15 1.68 3.05 2.66 2.77

TC BioPharm (Holdings) Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $2.77 Mil mean?
TC BioPharm (Holdings) (TCBWF) has a Current Accrued Expense of $2.77 Mil as of Dec. 2024. Current Accrued Expense records the total amount of accrued expenses. View historical data on TC BioPharm (Holdings) and its competitors.
Is TC BioPharm (Holdings)'s Current Accrued Expense too high?
TC BioPharm (Holdings)'s current Current Accrued Expense is $2.77 Mil.
How does TC BioPharm (Holdings)'s Current Accrued Expense compare to SIGY and CNBX?
TC BioPharm (Holdings)'s Current Accrued Expense of $2.77 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on TC BioPharm (Holdings) and its competitors. TC BioPharm (Holdings)'s current Current Accrued Expense is $2.77 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TC BioPharm (Holdings) stock overvalued right now?
TC BioPharm (Holdings) (TCBWF) has a current Current Accrued Expense of $2.77 Mil. The current Current Accrued Expense is $2.77 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For TC BioPharm (Holdings) (TCBWF), the current Current Accrued Expense is $2.77 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TC BioPharm (Holdings) Business Description

Address Maxim 1, 2 Parklands Way, Holytown, Motherwell, Scotland, GBR, ML1 4WR
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.